Penn Capital Management Company LLC Makes New Investment in LifeMD, Inc. $LFMD

Penn Capital Management Company LLC purchased a new stake in shares of LifeMD, Inc. (NASDAQ:LFMD) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 224,235 shares of the company’s stock, valued at approximately $926,000.

Several other institutional investors have also recently made changes to their positions in the company. Federated Hermes Inc. raised its position in shares of LifeMD by 278.1% in the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after buying an additional 721,018 shares in the last quarter. Prescott Group Capital Management L.L.C. bought a new stake in LifeMD during the fourth quarter valued at $2,344,000. Arrowstreet Capital Limited Partnership grew its position in LifeMD by 1,767.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock worth $5,924,000 after buying an additional 411,651 shares in the last quarter. JPMorgan Chase & Co. grew its position in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after buying an additional 352,004 shares in the last quarter. Finally, Whetstone Capital Advisors LLC increased its stake in LifeMD by 89.6% in the 4th quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock worth $2,397,000 after acquiring an additional 332,269 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

Wall Street Analyst Weigh In

LFMD has been the subject of a number of research analyst reports. BTIG Research dropped their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Lake Street Capital set a $5.00 target price on shares of LifeMD in a research note on Thursday, August 6th. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Finally, Mizuho set a $7.00 price target on shares of LifeMD in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, LifeMD has an average rating of “Moderate Buy” and an average price target of $7.57.

LifeMD Stock Down 3.7%

Shares of LFMD stock opened at $3.14 on Friday. The business has a 50-day moving average price of $3.94 and a two-hundred day moving average price of $3.96. LifeMD, Inc. has a 12-month low of $2.56 and a 12-month high of $7.32. The firm has a market cap of $151.35 million, a P/E ratio of -62.79 and a beta of 2.02.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. As a group, research analysts expect that LifeMD, Inc. will post -0.48 EPS for the current fiscal year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.